<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lazelle RA</submitter><funding>NIDDK NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>1456-64</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4849833</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(5)</volume><pubmed_abstract>Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disru</pubmed_abstract><journal>Journal of the American Society of Nephrology : JASN</journal><pubmed_title>Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.</pubmed_title><pmcid>PMC4849833</pmcid><funding_grant_id>R01 DK095841</funding_grant_id><funding_grant_id>T32 DK067864</funding_grant_id><funding_grant_id>T32 GM071338</funding_grant_id><funding_grant_id>R01 DK051496</funding_grant_id><pubmed_authors>Terker AS</pubmed_authors><pubmed_authors>Blankenstein KI</pubmed_authors><pubmed_authors>Himmerkus N</pubmed_authors><pubmed_authors>Ellison DH</pubmed_authors><pubmed_authors>Lazelle RA</pubmed_authors><pubmed_authors>Yang CL</pubmed_authors><pubmed_authors>Bleich M</pubmed_authors><pubmed_authors>McCully BH</pubmed_authors><pubmed_authors>Mutig K</pubmed_authors><pubmed_authors>Bachmann S</pubmed_authors></additional><is_claimable>false</is_claimable><name>Renal Deletion of 12 kDa FK506-Binding Protein Attenuates Tacrolimus-Induced Hypertension.</name><description>Tacrolimus is a widely used immunosuppressive drug that inhibits the phosphatase calcineurin when bound to the 12 kDa FK506-binding protein (FKBP12). When this binding occurs in T cells, it leads to immunosuppression. Tacrolimus also causes side effects, however, such as hypertension and hyperkalemia. Previously, we reported that tacrolimus stimulates the renal thiazide-sensitive sodium chloride cotransporter (NCC), which is necessary for the development of hypertension. However, it was unclear if tacrolimus-induced hypertension resulted from tacrolimus effects in renal epithelial cells directly or in extrarenal tissues, and whether inhibition of calcineurin was required. To address these questions, we developed a mouse model in which FKBP12 could be deleted along the nephron. FKBP12 disru</description><dates><release>2016-01-01T00:00:00Z</release><publication>2016 May</publication><modification>2025-04-04T07:30:39.012Z</modification><creation>2019-03-27T02:12:40Z</creation></dates><accession>S-EPMC4849833</accession><cross_references><pubmed>26432904</pubmed><doi>10.1681/ASN.2015040466</doi><doi>10.1681/asn.2015040466</doi></cross_references></HashMap>